Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids - PubMed (original) (raw)
doi: 10.1038/nm.3802. Epub 2015 Feb 23.
Affiliations
- PMID: 25706875
- DOI: 10.1038/nm.3802
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids
Mami Matano et al. Nat Med. 2015 Mar.
Abstract
Human colorectal tumors bear recurrent mutations in genes encoding proteins operative in the WNT, MAPK, TGF-β, TP53 and PI3K pathways. Although these pathways influence intestinal stem cell niche signaling, the extent to which mutations in these pathways contribute to human colorectal carcinogenesis remains unclear. Here we use the CRISPR-Cas9 genome-editing system to introduce multiple such mutations into organoids derived from normal human intestinal epithelium. By modulating the culture conditions to mimic that of the intestinal niche, we selected isogenic organoids harboring mutations in the tumor suppressor genes APC, SMAD4 and TP53, and in the oncogenes KRAS and/or PIK3CA. Organoids engineered to express all five mutations grew independently of niche factors in vitro, and they formed tumors after implantation under the kidney subcapsule in mice. Although they formed micrometastases containing dormant tumor-initiating cells after injection into the spleen of mice, they failed to colonize in the liver. In contrast, engineered organoids derived from chromosome-instable human adenomas formed macrometastatic colonies. These results suggest that 'driver' pathway mutations enable stem cell maintenance in the hostile tumor microenvironment, but that additional molecular lesions are required for invasive behavior.
Comment in
- Toward recreating colon cancer in human organoids.
Salahudeen AA, Kuo CJ. Salahudeen AA, et al. Nat Med. 2015 Mar;21(3):215-6. doi: 10.1038/nm.3818. Nat Med. 2015. PMID: 25742455 No abstract available.
Similar articles
- Chromosome Engineering of Human Colon-Derived Organoids to Develop a Model of Traditional Serrated Adenoma.
Kawasaki K, Fujii M, Sugimoto S, Ishikawa K, Matano M, Ohta Y, Toshimitsu K, Takahashi S, Hosoe N, Sekine S, Kanai T, Sato T. Kawasaki K, et al. Gastroenterology. 2020 Feb;158(3):638-651.e8. doi: 10.1053/j.gastro.2019.10.009. Epub 2019 Oct 14. Gastroenterology. 2020. PMID: 31622618 - Sequential cancer mutations in cultured human intestinal stem cells.
Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H, Korving J, van de Wetering M, Schwank G, Logtenberg M, Cuppen E, Snippert HJ, Medema JP, Kops GJ, Clevers H. Drost J, et al. Nature. 2015 May 7;521(7550):43-7. doi: 10.1038/nature14415. Epub 2015 Apr 29. Nature. 2015. PMID: 25924068 - CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.
Takeda H, Kataoka S, Nakayama M, Ali MAE, Oshima H, Yamamoto D, Park JW, Takegami Y, An T, Jenkins NA, Copeland NG, Oshima M. Takeda H, et al. Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15635-15644. doi: 10.1073/pnas.1904714116. Epub 2019 Jul 12. Proc Natl Acad Sci U S A. 2019. PMID: 31300537 Free PMC article. - Sequence of molecular genetic events in colorectal tumorigenesis.
Laurent-Puig P, Blons H, Cugnenc PH. Laurent-Puig P, et al. Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S39-47. Eur J Cancer Prev. 1999. PMID: 10772417 Review. - RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B. Fang B. Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38. doi: 10.1093/abbs/gmv090. Epub 2015 Sep 7. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26350096 Free PMC article. Review.
Cited by
- Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.
Song Z, Tao Y, Liu Y, Li J. Song Z, et al. Front Immunol. 2024 Aug 30;15:1444437. doi: 10.3389/fimmu.2024.1444437. eCollection 2024. Front Immunol. 2024. PMID: 39281673 Free PMC article. Review. - XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.
Leto SM, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, Zanella ER, Borgato S, Corti G, di Blasio L, Somale D, Vara-Messler M, Galimi F, Sassi F, Lupo B, Catalano I, Pinnelli M, Viviani M, Sperti L, Mellano A, Ferrero A, Zingaretti CC, Puliafito A, Primo L, Bertotti A, Trusolino L. Leto SM, et al. Nat Commun. 2024 Aug 29;15(1):7495. doi: 10.1038/s41467-024-51909-2. Nat Commun. 2024. PMID: 39209908 Free PMC article. - Interpretation of the past, present, and future of organoid technology: an updated bibliometric analysis from 2009 to 2024.
Qu B, Mu Q, Bi H, Chen Y, Wang Q, Ma X, Lu L. Qu B, et al. Front Cell Dev Biol. 2024 Aug 13;12:1433111. doi: 10.3389/fcell.2024.1433111. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39193361 Free PMC article. - The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors.
Li P, Ma X, Gu X. Li P, et al. Front Cell Dev Biol. 2024 Aug 5;12:1442193. doi: 10.3389/fcell.2024.1442193. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39161590 Free PMC article. Review. - Organoids: new frontiers in tumor immune microenvironment research.
Yang Y, Cui J, Kong Y, Hou Y, Ma C. Yang Y, et al. Front Immunol. 2024 Jul 29;15:1422031. doi: 10.3389/fimmu.2024.1422031. eCollection 2024. Front Immunol. 2024. PMID: 39136020 Free PMC article. Review.
References
- Blood. 2002 Nov 1;100(9):3175-82 - PubMed
- Cancer Cell. 2013 Jul 8;24(1):15-29 - PubMed
- Cancer Res. 2000 Dec 15;60(24):6886-9 - PubMed
- Nat Biotechnol. 2014 Sep;32(9):941-6 - PubMed
- Science. 2013 Jun 7;340(6137):1190-4 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous